Want to see LGND full AI Analyst Report?
Ligand Pharma (LGND) Income Statement
Ligand Pharma Income Statement
Last quarter (Q3 2026), Ligand Pharma's total revenue was $78.75M, a decrease of 31.80% from the same quarter last year. In Q3, Ligand Pharma's net income was $-28.48M. See Ligand Pharma’s key income statements, including revenue, expenses, profit, and income.
| Income Statement | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| $ 268.09M | $ 167.13M | $ 131.31M | $ 196.25M | $ 241.54M | |
| $ 261.50M | $ 156.06M | $ 96.27M | $ 143.42M | $ 179.37M | |
| $ 214.30M | $ 178.66M | $ 84.32M | $ 140.38M | $ 75.52M | |
| Depreciation and Amortization | $ 33.77M | $ 35.24M | $ 36.52M | $ 43.39M | $ 50.95M |
| $ 192.74M | $ 40.79M | $ 100.84M | $ 81.20M | $ 142.77M | |
| $ 47.20M | $ -22.61M | $ 11.94M | $ 3.04M | $ 103.85M | |
| $ 111.76M | $ 25.12M | $ 51.72M | $ 32.97M | $ -31.65M | |
| $ 158.96M | $ 2.52M | $ 63.66M | $ 36.01M | $ 72.20M | |
| $ 124.45M | $ -4.03M | $ 52.15M | $ -33.36M | $ 57.14M | |
| Per Share Metrics | |||||
| Basic EPS | $ 6.44 | $ -0.22 | $ 3.02 | $ -1.98 | $ 3.46 |
| Diluted EPS | $ 6.13 | $ -0.22 | $ 2.94 | $ -1.98 | $ 3.34 |
| Weighted Average Shares Outstanding | 19.34M | 18.29M | 17.30M | 16.87M | 16.63M |
| Weighted Average Shares Outstanding (Diluted) | 20.29M | 18.29M | 17.76M | 16.87M | 17.25M |
Currency in USD